ADCY1 and cancer: In addition, pharmacological inhibition of the AC1 by a selective AC1 inhibitor, NB001, has been reported to produce powerful analgesic effects on different animal models of chronic pain including neuropathic pain, inflammatory pain, cancer pain, arthralgia, gout-related pain, visceral pain, and headache [7–12].